Physician profile
Christopher Logan
NPI 1639710148
$8,491.30
in general payments reported to CMS, 2019-2025
34 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,201 · 2022: $1,308 · 2023: $1,954 · 2024: $1,755 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,733 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,732.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,928.98 | 2021-2025 | |
| Novo Nordisk INC | $1,136.04 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $868.48 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $774.34 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $610.22 | 2022-2025 | |
| Pfizer INC. | $511.19 | 2023-2025 | |
| Antares Pharma, INC. | $324.91 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $298.69 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Shield Therapeutics INC | $258.84 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $203.40 | 2021 | |
| Axsome Therapeutics, INC. | $194.02 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $135.59 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $135.32 | 2021-2023 | Trintellix |
| Amarin Pharma, INC. | $128.01 | 2021-2023 | |
| Exact Sciences Corporation | $124.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $78.37 | 2021 | |
| Halozyme INC | $62.62 | 2023 | |
| Acerus Pharmaceuticals Corporation | $58.97 | 2021-2022 | |
| Clarus Therapeutics INC. | $56.62 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.23 | 2025 | Caplyta |
| Azurity Pharmaceuticals, INC. | $50.43 | 2023-2024 | Edarbi, Edarbi |
| Astellas Pharma US INC | $49.29 | 2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $49.22 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $48.33 | 2021-2025 | Capvaxive, Gardasil 9 |
| Arbor Pharmaceuticals, INC. | $47.73 | 2021-2022 | |
| Esperion Therapeutics, INC. | $47.60 | 2021-2024 | Nexletol |
| Amgen INC. | $44.41 | 2025 | Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $41.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $36.65 | 2021-2022 | |
| Tolmar, INC. | $32.51 | 2025 | Jatenzo |
| Inspire Medical Systems, INC. | $30.18 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $28.51 | 2022 | |
| Corcept Therapeutics | $25.11 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $15.15 | 2025 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Logan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.